Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tabelecleucel

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Grants Priority Review For Pierre Fabre's Tabelecleucel BLA
    FDA Grants Priority Review For Pierre Fabre's Tabelecleucel BLA

    18 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-inc-announces-the-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-tabelecleucel-tab-cel-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferat-302200702.html

    PR NEWSWIRE
    18 Jul 2024
    Share Share
    FDA Accepts Atara's BLA For Tab-cel With Priority Review
    FDA Accepts Atara's BLA For Tab-cel With Priority Review

    17 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240717492765/en

    BUSINESSWIRE
    17 Jul 2024
    Share Share
    Atara Biotherapeutics’ Ebvallo™ Wins Prix Galien Award for Orphan/Rare Diseases
    Atara Biotherapeutics’ Ebvallo™ Wins Prix Galien Award for Orphan/Rare Diseases

    21 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240621317043/en

    BUSINESSWIRE
    21 Jun 2024
    Share Share
    Pierre Fabre announces the submission by Atara of Tabelecleucel (Tab-cel®)
    Pierre Fabre announces the submission by Atara of Tabelecleucel (Tab-cel®)

    20 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-laboratories-announces-the-submission-by-atara-biotherapeutics-of-tabelecleucel-tab-cel-biologics-license-application-for-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-with-u-302149982.html

    PR NEWSWIRE
    20 May 2024
    Share Share
    Atara Submits Tab-cel BLA For Transplant Lymphoproliferative Disease
    Atara Submits Tab-cel BLA For Transplant Lymphoproliferative Disease

    20 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240520985176/en

    BUSINESSWIRE
    20 May 2024
    Share Share
    Pierre Fabre's Ebvallo (tabelecleucel) Receives Approval in Europe
    Pierre Fabre's Ebvallo (tabelecleucel) Receives Approval in Europe

    10 Mar 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/ebvallo-epar-medicine-overview_en.pdf

    EMA
    10 Mar 2023
    Share Share